Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung cancer
Phase 1
- Conditions
- advanced or recurrent non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000005226
- Lead Sponsor
- School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)other active disease 2)pregnancy 3)previous administration of GEM 4)active bleeding or hematological disorders 5)HBV,HCV,HIV carriers 6)active infection 7)progressive brain, meningeal or bone metastasis 8)autoimmnune disorders 9)drug allergies 10)During treatment with immunosuppressive agents 11)interstitial pneumonia 12)Severe psychiatric disease 13)Patients whom doctors judged inadequate to the enrollment of this study by other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method Response rate Progression free survival Overall survival Immune induction